{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Tandutinib",
  "nciThesaurus": {
    "casRegistry": "387867-13-2",
    "chebiId": "",
    "chemicalFormula": "C31H42N6O4",
    "definition": "A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis.",
    "fdaUniiCode": "E1IO3ICJ9A",
    "identifier": "C48404",
    "preferredName": "Tandutinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1967"
    ],
    "synonyms": [
      "1-Piperazinecarboxamide, 4-(6-Methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-",
      "CT53518",
      "MLN 518",
      "MLN518",
      "TANDUTINIB",
      "Tandutinib",
      "tandutinib"
    ]
  }
}